10-Q: TerrAscend Reports Q1 2026 Results, Navigates Regulatory Shifts

TerrAscend Corp. reported Q1 2026 results with a slight revenue increase, while managing operational exits and anticipating potential tax relief from cannabis rescheduling.

Summary

• TerrAscend Corp. reported net revenue of $65.5 million for the first quarter ended March 31, 2026, a 2% increase from $64.3 million in the same period of 2025.
• The company experienced a net loss of $8.0 million for the quarter, compared to a net loss of $12.3 million in Q1 2025.
• Operating cash flow from continuing operations was $8.7 million, a decrease from $11.2 million in the prior year's quarter.
• The company is finalizing its exit from the Michigan market, which resulted in a loss from discontinued operations of $1.2 million.
• Significant developments include the potential impact of the reclassification of medical cannabis to Schedule III under the U.S. Controlled Substances Act, which could provide retrospective tax relief related to Section 280E.
• The company completed the acquisition of a 35% interest in Union Chill Cannabis Company LLC in New Jersey for $13 million.
• As of March 31, 2026, cash and cash equivalents stood at $39.0 million.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, reflecting a mixed operational performance with slight revenue growth but persistent net losses and increasing tax liabilities, offset by positive developments in potential regulatory and tax relief.

Positives

• Revenue increased by 2% to $65.5 million in Q1 2026 compared to Q1 2025.
• Retail revenue saw a significant increase of $5.6 million, driven by acquisitions and organic growth.
• Net loss improved to $8.0 million from $12.3 million in the prior year's quarter.
• The company is in compliance with its financial covenant on its primary loan.
• The potential reclassification of medical cannabis to Schedule III could lead to significant tax benefits and retrospective relief.
• The company completed the acquisition of Union Chill, expanding its New Jersey operations.

Negatives

• Wholesale revenue decreased by $4.3 million due to increased competition and price compression.
• Cost of sales increased by 4% to $30.9 million, outpacing revenue growth.
• General and administrative expenses increased by 2% to $21.5 million.
• Finance and other expenses increased by 12% to $9.3 million, primarily due to increased interest and accretion on the FG Loan.
• The company incurred a loss from discontinued operations related to its Michigan exit.
• The company received a notice from the DOJ regarding a federal income tax refund for the 2020 tax year, seeking repayment of approximately $9.5 million plus interest.

Risks

• The ongoing illegality of cannabis under U.S. federal law continues to pose risks, particularly concerning Section 280E of the Internal Revenue Code.
• Increased competition and price compression in the wholesale market are impacting revenue.
• The company is undergoing a receivership process for its Michigan entities, which could impact its consolidation of these entities.
• The ultimate impact of the cannabis rescheduling and potential IRS guidance remains uncertain.
• The company faces risks related to its substantial debt obligations, including the FocusGrowth Term Loan.
• The company's ability to obtain additional financing on acceptable terms is a stated concern.

Future Outlook

The company believes its existing cash balances will be sufficient to meet its anticipated cash requirements for at least the next 12 months. Future funding is expected from ongoing operations, equity/debt offerings, additional debt, sale of real property, sale-leaseback transactions, and exercise of options/warrants. The company is actively assessing the potential financial statement impacts of the cannabis rescheduling and related tax implications, but the ultimate effect remains uncertain.

Management Comments

• The company is continuing to assess the potential financial statement impacts and is unable to reasonably estimate the ultimate effect at this time regarding the cannabis rescheduling and potential tax relief.
• Management believes its existing cash balances will be sufficient to meet its anticipated cash requirements from the date of this Annual Report through at least the next 12 months.
• The company remains in a strong financial position, with resources available for reinvesting in existing businesses, conducting acquisitions, and managing its capital structure on a short and long-term basis.

Industry Context

StockSavvy.ai notes that TerrAscend's Q1 2026 results reflect the ongoing evolution of the North American cannabis market, characterized by increasing retail strength, persistent wholesale competition, and significant regulatory shifts. The potential rescheduling of cannabis to Schedule III in the U.S. is a pivotal development that could fundamentally alter the tax landscape for cannabis companies, particularly concerning Section 280E, which has historically burdened profitability.

Comparison to Industry Standards

• TerrAscend's gross profit margin of 52.8% is within the typical range for vertically integrated cannabis operators, though it has seen slight compression from 53.9% in the prior year due to wholesale price pressures.
• The company's net loss from continuing operations of $6.8 million highlights the ongoing challenge of achieving consistent profitability in the U.S. cannabis sector, where high operating costs and regulatory complexities persist.
• The company's Adjusted EBITDA from continuing operations of $17.4 million indicates a strong operational performance before accounting for non-cash items and specific expenses, a common metric used for valuation in the cannabis industry.
• The significant increase in uncertain tax positions and liabilities ($138.8 million) reflects the industry-wide challenge of navigating U.S. federal tax laws, particularly Section 280E, which differs significantly from international tax treatment of similar industries.

Management Changes

Legal Proceedings

• The company is involved in a number of lawsuits incidental to its business, including litigation related to intellectual property, product liability, employment, and commercial matters. Management believes any ultimate liability would not have a material adverse effect.
• As of March 31, 2026, there were no pending lawsuits that could reasonably be expected to have a material effect on the results of the Company's Consolidated Financial Statements.
• The company received correspondence from the U.S. Department of Justice (DOJ) on April 6, 2026, related to a federal income tax refund for the 2020 tax year, seeking repayment of approximately $9.5 million plus interest. The company is evaluating the matter and believes it has substantive defenses.

Related Party Transactions

• Entities controlled by the Company's Executive Chairman, Jason Wild, have invested approximately $7,100 in the FG Loan as Lenders and are members of the loan syndicate.

Stakeholder Impact

• Shareholders: Potential for improved future profitability if tax relief from cannabis rescheduling materializes; ongoing net losses and debt obligations present risks.
• Employees: Restructuring costs related to Michigan exit may impact employees in that region; new CFO appointment could signal strategic shifts.
• Creditors: The company is in compliance with its primary loan covenant, but the Michigan receivership and DOJ inquiry introduce potential complexities.
• Suppliers: No specific impact mentioned, but operational changes and financial performance could indirectly affect supplier relationships.

Next Steps

• Finalizing exit from the Michigan market.
• Continuing to assess the financial statement impacts of the cannabis rescheduling and potential tax relief.
• Evaluating the accounting impact of the receivership in Michigan.
• Monitoring the new expedited hearing process for medical and adult-use cannabis.
• Continuing to manage debt obligations and explore future financing options.

Key Dates

Recommendation

TerrAscend's Q1 2026 results show modest revenue growth and an improved net loss, but persistent wholesale challenges and significant tax uncertainties remain. The potential for tax relief due to cannabis rescheduling is a major positive catalyst, but the DOJ inquiry and Michigan receivership introduce considerable near-term risk. Given the mixed operational performance and the high degree of regulatory and legal uncertainty, a 'hold' recommendation is appropriate pending further clarity on the tax implications and resolution of legal matters.

Keywords

TerrAscend, Cannabis, SEC Filing, 10-Q, Financial Results, Revenue, Net Loss, Section 280E, Tax Relief, Acquisition, Michigan Exit, Schedule III, US Cannabis Market